Nutritional composition for regulating emotion as well as preparation method, product and application of nutritional composition

Abstract

The invention discloses a nutritional composition for regulating emotion as well as a preparation method, a product and application thereof, and relates to the technical field of food. The nutritional composition provided by the invention comprises lactoferrin and 2 '-fucosyllactose, and the weight ratio of the lactoferrin to the 2'-fucosyllactose is 1: (2-9). The preparation method comprises the following steps: mixing the lactoferrin and the 2 '-fucosyllactose in proportion, and sieving. The invention also provides a product containing the nutritional composition. The invention also discloses an application of the nutritional composition and the product in preparation of a formula B or a medicine for treating depression and anxiety disorder. Animal experiments prove that the combination of the lactoferrin and the 2 '-fucosyllactose has a curative effect in the aspect of treating depression and anxiety disorder, and particularly, the medicine effect is better under a specific ratio.

Description

Technical Field

[0001] The present invention relates to the field of food technology, and in particular to a nutrient composition for regulating mood, a preparation method thereof, a product and application thereof. Background Art

[0002] In recent years, with the accelerated pace of people's work and life and the intensified competition, the prevalence of mental illnesses such as depression and anxiety that seriously endanger human physical and mental health has increased year by year. Depression seriously endangers human life and health. Depression refers to a type of mood disorder syndrome with low mood, slow thinking, and psychomotor retardation symptoms such as decreased interest and decreased initiative as the main manifestations. The incidence rate is very high, with a lifetime prevalence of about 15-17%, and it has been increasing year by year in recent years; depression has caused a huge burden on society, family and patients themselves, and seriously endangers human life and health. Therefore, the prevention and treatment of depression is a major public health issue. Although anxiety and depression are divided into two mental illnesses in medicine, they often coexist in clinical practice and are sometimes difficult to distinguish. Therefore, many scholars recommend combined treatment of the two.

[0003] Biological factors that cause depression and anxiety symptoms: Emotional depression has a certain neurobiological basis, the most important of which is the reduction of the content of neurotransmitters such as serotonin and norepinephrine in the brain, which leads to depression. At present, the treatment of depression faces serious challenges. The treatment of depression mainly relies on drug therapy; although there are many effective antidepressants in clinical practice, they still cannot meet the needs of treatment. In particular, there are serious problems with the current antidepressants: 1. Slow onset, generally 3-6 weeks after taking the medicine to improve clinical symptoms, and long-term medication is required to cure; usually it is difficult for patients to persist until the drug takes effect and give up treatment, which is also the main reason for the poor clinical effect of depression treatment. 2. There are many side effects; 3. At least 35% of patients with depression do not respond to current drug treatments; 4. Expensive. Therefore, finding drugs that have both preventive and therapeutic effects on the onset of depression and / or anxiety and have low adverse reactions has become a scientific research problem that urgently needs to be solved.

[0004] For example, Chinese patent CN 109172612 A provides a biological preparation for preventing and treating mental disorders based on photosynthetic bacteria. The preparation belongs to a probiotic agent capable of preventing and treating mental disorders, such as depression and / or anxiety, and has both preventive and therapeutic effects on the onset of mental disorders, such as depression and / or anxiety, and has no adverse reactions. A new approach to preventing and treating mental disorders, such as depression and / or anxiety, has been developed.

[0005] Chinese patent CN 114392260 A provides a drug for relieving anxiety and depression, the main active ingredient of which is a whole herb extract of Lycopodiella cernua. The specific technical scheme is as follows: a drug for relieving anxiety and depression, the raw materials of which include ethanol and / or methanol extracts of Lycopodiella cernua, which are rich in alkaloids, have nerve cell protection function and anti-acetylcholinesterase activity, and can relieve anxiety and depression.

[0006] Based on the urgency of finding new and effective drugs for treating depression and anxiety, the researchers of the present invention provide a nutritional composition for regulating mood, the active components of which are lactoferrin (LF) and 2'-fucosyllactose (2'-FL). Lactoferrin is an iron-binding glycoprotein in the transferrin family, present in human milk and various secretions, with the highest content in breast milk. 2-Fucosyllactose is a non-reducing trisaccharide composed of lactose and L-fucose. The researchers of the present invention found in experiments that the two components LF and 2'-FL have a synergistic effect in the treatment of anxiety or depression, and the nutritional composition composed of the two in a specific ratio is effective in treating depression. Summary of the invention

[0007] In view of the above problems, the present invention provides a nutritional composition for regulating mood, wherein the active components include lactoferrin and 2'-fucosyllactose. By screening the specific ratio and optimizing the preparation process, a nutritional composition for regulating mood with good medicinal effect is obtained.

[0008] To achieve the above purpose, the technical solution adopted by the present invention is as follows:

[0009] In one aspect, the present invention provides a nutritional composition for regulating mood, comprising lactoferrin and 2'-fucosyllactose in a weight ratio of 1:2-9.

[0010] Preferably, the weight ratio of lactoferrin to 2'-fucosyllactose may be 1:2-6; further preferably, the weight ratio of lactoferrin to 2'-fucosyllactose may be 1:6.

[0011] In another aspect, the present invention provides a product comprising the above-mentioned nutritional composition, which is at least one of a food, a medicine and a nutritional product.

[0012] The pharmaceutical carrier used can be solid, liquid or gas. Examples of solid carriers include lactose, kaolin, sucrose, talc, gelatin, agar, pectin, gum arabic, magnesium stearate and stearic acid. Examples of liquid carriers include syrup, peanut oil, olive oil and water. Examples of gaseous carriers include carbon dioxide and nitrogen.

[0013] When preparing the composition for oral dosage form, any convenient pharmaceutical medium can be used. For example, water, ethanol, oil, alcohol, flavoring agent, preservative, coloring agent, etc. can be used to form oral liquid preparations, such as suspensions, elixirs and solutions; while carriers, such as starch, sugars, microcrystalline cellulose, diluents, granulating agents, emulsifiers, lubricants, binders, disintegrants can be used to form oral solid preparations, such as powders, capsules and tablets. Tablets and capsules are preferred oral dosage units using solid pharmaceutical carriers due to their ease of administration. Tablets can be coated using standard aqueous or non-aqueous techniques.

[0014] Tablets containing the Chinese medicine composition of the present invention can be prepared by tableting or molding, and one or more auxiliary ingredients or adjuvants can be used. The active ingredient can be tableted in a free-flowing form (such as powder or granules) in a suitable machine, and can be mixed with an adhesive, a lubricant, an inert diluent, a surfactant or a dispersant to prepare a tablet. Molded tablets can be molded in a suitable machine, i.e., a powdered compound mixture moistened with an inert liquid diluent. Each tablet preferably contains about 0.05 mg to about 5 g of active ingredient, and each sachet or capsule preferably contains about 0.05 mg to about 5 g of active ingredient. For example, a preparation intended for oral administration to humans may contain about 0.5 mg to about 5 g of active drug, mixed with an appropriate and convenient carrier material, which may account for about 5% to 95% of the total composition. The unit dosage form usually contains about 1 mg to about 2 g of active ingredient, usually 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg or 1000 mg.

[0015] The pharmaceutical composition suitable for parenteral administration of the present invention can be prepared as an aqueous solution or suspension of the active compound. Suitable surfactants such as hydroxypropylcellulose can be included. Dispersions can also be prepared in glycerol, liquid polyethylene glycol and oil mixtures thereof. In addition, preservatives can be added to prevent harmful growth of microorganisms.

[0016] Medicine of the present invention can be in the form suitable for topical use, for example aerosol, cream, ointment, lotion, powder or the like. In addition, composition can be in the form suitable for transdermal administration device. Can use Chinese medicine composition of the present invention, prepare these prescriptions by conventional processing method. For example, by mixing hydrophilic material and water, and about 5wt% to about 10wt% of compound, prepare cream or ointment with required consistency.

[0017] The medicine of the present invention can be in a form suitable for rectal administration, wherein the carrier is a solid. Preferably, the mixture is made into a unit dose suppository. Suitable carriers include cocoa butter and other materials commonly used in the art. Suppositories can be prepared by first forming a composition containing a softened or melted carrier, followed by cooling and shaping in a mold.

[0018] In addition to the above-mentioned carrier components, the above-mentioned pharmaceutical preparations may include (if applicable) one or more additional carrier components, such as diluents, buffers, flavoring agents, adhesives, surfactants, thickeners, lubricants, preservatives (including antioxidants), etc. In addition, other excipients, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, etc., colorants and flavoring agents, etc., may be added. The preparation is made isotonic with the blood of the intended recipient. The components containing the Chinese medicine composition of the present invention can also be prepared in the form of powder or concentrate.

[0019] Preferably, the pharmaceutical preparation is an oral pharmaceutical preparation.

[0020] More preferably, the oral pharmaceutical preparation includes pills, capsules, granules, oral liquids, powders, tablets, lozenges, and lozenges. Further preferably, the dosage form is selected from capsules, tablets, or pills.

[0021] More preferably, the auxiliary material includes at least one of a disintegrant, a filler, a flavoring agent, a pH adjuster, a lubricant, and an antioxidant.

[0022] Preferably, the disintegrant can be selected from at least one of povidone, polyvinyl alcohol, low molecular weight HPC (hydroxypropyl cellulose), low molecular weight HPMC (hydroxypropyl methylcellulose), low molecular weight hydroxymethyl, cellulose acetate, gelatin, hydrolyzed gelatin, polyethylene oxide, gum arabic, and dextrin.

[0023] Preferably, the filler can be selected from at least one of microcrystalline cellulose, lactose, glucose, galactose, fructose, sucrose, calcium hydrogen phosphate, sorbitol, mannitol, lactitol, xylitol, isomalt, erythritol, and hydrogenated starch hydrolysate.

[0024] Preferably, the flavoring agent can be selected from at least one of sucrose, fructose, aspartame, apple flavor, sorbitol, glucose, isomalt, and erythritol.

[0025] Preferably, the pH adjuster can be selected from at least one of citric acid, potassium citrate, lactic acid, tartaric acid, fumaric acid and sodium citrate.

[0026] Preferably, the lubricant is selected from at least one of magnesium stearate, silicon dioxide, polyethylene glycol, talc, and micro-powdered silica gel.

[0027] Preferably, the antioxidant can be selected from at least one of L-cysteine ​​hydrochloride, L-cysteine ​​base, 4,4 (2,3-dimethyltetramethylene dicatechol), tocopherol-rich extract (natural vitamin E), α-tocopherol (synthetic vitamin E), B-tocopherol, 6-tocopherol, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), propyl gallate, octyl gallate, dodecyl gallate, tert-butylhydroquinone (TBHQ), fumaric acid, malic acid, ascorbic acid (vitamin C), sodium ascorbate, calcium ascorbate, potassium ascorbate, ascorbyl palmitate, and ascorbyl stearate.

[0028] In another aspect, the present invention provides a method for preparing the above-mentioned nutritional composition, comprising the following steps: mixing lactoferrin and 2'-fucosyllactose in proportion, and sieving.

[0029] On the other hand, the present invention provides the use of the above-mentioned nutritional composition or the above-mentioned product in the preparation of a drug for preventing or treating anxiety and depression.

[0030] Preferably, the depression includes but is not limited to psychogenic depression, endogenous depression, hypochondriacal depression, anxious depression, pseudodementia-type depression, and chronic depression.

[0031] Preferably, the depression includes but is not limited to the following symptoms: 1) psychological changes: mood changes, intense sadness, despair, mental dullness, inattention, pessimism, agitation, anxiety, irritability, guilt, worthlessness, suicidal thoughts or attempts; 2) physical symptoms: insomnia, anorexia, decreased appetite, weight loss, weight gain, decreased energy and libido, fatigue, irritability, pain, cramps.

[0032] Terms and Claims of the Present Invention:

[0033] 1. As used herein, the articles “a”, “an” and “the” include plural referents unless expressly limited to one or more referents otherwise.

[0034] 2. As used herein, numerical range: Unless otherwise expressly indicated, all ranges or ratios disclosed herein will be understood to include any and all sub-ranges or sub-ratios contained therein. For example, a range or ratio of 1 to 30 stated should be considered to be included between a minimum value of 1 and a maximum value of 30, and any sub-range or sub-ratio, integer, decimal, or sub-range or sub-ratio consisting of integers or decimals including the end points.

[0035] 3. As used herein, the terms "comprises," "including," "have," "have," "may," "contain" and variations thereof mean open-ended conjunctions or terms that do not exclude the possibility of additional compositions or structures.

[0036] Compared with the prior art, the present invention has the following beneficial effects:

[0037] The present invention provides a nutritional composition for regulating mood, wherein the active components include lactoferrin and 2'-fucosyllactose, and animal experiments have shown that the combination of the two can treat depression and anxiety, and the efficacy is better in particular under a specific ratio. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 A graph showing the time mice spent in the middle area of ​​the open field.

[0039] Figure 2 A graph showing the distance traveled by mice in the open field.

[0040] Figure 3 This is a graph showing the number of times mice entered the middle area of ​​the open field.

[0041] Figure 4 A graph showing the time mice spent in the open arms.

[0042] Figure 5 A graph showing the time mice spent immobile in the elevated maze.

[0043] Figure 6 Graph showing the ratio of mice entering the open arms to the closed arms.

[0044] Figure 7 This is a graph showing the time mice spend in the light box.

[0045] Figure 8 This is the time when the mouse first entered the dark chamber from the light chamber.

[0046] Fig. 9 A graph showing the number of times the mouse crossed the light and dark boxes.

[0047] Fig.10 This is a graph of the immobility time of mice during tail suspension. DETAILED DESCRIPTION

[0048] In order to make the technical means, creative features, purpose and effect of the present invention easy to understand, the present invention is further explained below in conjunction with specific embodiments, but the following embodiments are only preferred embodiments of the present invention, not all. Based on the embodiments in the implementation mode, other embodiments obtained by those skilled in the art without making creative work all belong to the protection scope of the present invention. It is worth noting that the raw materials used in the present invention are all common commercial products, and their sources are not specifically limited. The technology and scientific terms used in the embodiments have the meanings commonly understood by those of ordinary skill in the art to which the present invention belongs.

[0049] The prebiotics used in the present invention are 2'-fucosyllactose (2'-FL) purchased from DSM (DSM, Netherlands) and lactoferrin (LF) purchased from Warrnambool Cheese & Butter Factory.

[0050] Embodiment 1:

[0051] This experiment was reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of the Institute of Brain Cognition and Brain Diseases (BCBDI), Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, with the ethics number SIAT-IACUC-20211222-NS-NTPZX-WLP-A2090-01. 7-week-old adult C57BL / 6J male mice (n=30) were purchased from Zhejiang Weitong Lihua.

[0052] After one week of environmental adaptation, 30 adult male C57BL / 6 mice in each batch were given samples of single components or different formulations by long-term oral gavage for 5 weeks. Then, in the fourth week of intervention, the mice were subjected to 1 week of stress induction. The blank control group was not intervened, and then their fecal samples were collected; finally, behavioral tests were performed, and the mice were continuously sampled during the above evaluation experiment. After the behavioral test, all animals will be handled and samples will be collected, including brain organs, blood samples, cecal colon tissues and bone samples. The collected samples will be further analyzed.

[0053] The stress response program is as follows:

[0054] a) Foot stimulation 10 times (current 0.5 mA, each time lasting 2 seconds, each time interval 10 seconds);

[0055] b) Tail suspension for 30 minutes;

[0056] c) Restrain for 1 hour.

[0057] The components or compositions involved in each group in the experiment are as follows:

[0058] a) Blank control group: intragastric administration of normal saline

[0059] b) Model group: intragastric administration of normal saline

[0060] c) Intervention 1 + model group: intragastrically administered 1200 mg / kg / d 2'-fucosyllactose (2'-FL)

[0061] d) Intervention 2+ model group: intragastric administration of 200 mg / kg / d lactoferrin (LF)

[0062] e) Intervention 3+ model group: oral administration of 1200 mg / kg / d 2'-FL and 200 mg / kg / d LF

[0063] The mouse intervention dose was converted based on the human intervention dose using the body surface area method. Based on the principle that the intervention dose per kilogram of body weight per square meter of body surface area is equal, the mouse dose is 6.67 times that of infants and young children. The doses of 2'-FL and LF used in infants and young children are 180 mg / kg / day and 16.2 mg / kg / day, respectively, so the mouse 2'-FL and LF doses are 1200 mg / kg / d and 200 mg / kg / d, respectively.

[0064] 1. Anxiety-like behavior test

[0065] 1) Open field test

[0066] The open field consists of a square box (35cm*35cm*30cm), which is divided into 16 areas (8.75cm*8.75cm), and the 4 areas in the middle will be defined as the middle area (17.5cm*17.5cm). Mice will be randomly placed in the middle area of ​​the open field. After 10 minutes of exploration, the time the mice stay in the middle area will be recorded and used as an indicator of anxiety. The longer the mice stay in the middle area, the lower their anxiety level.

[0067] 2) Elevated maze

[0068] The elevated maze device is a cross-shaped maze with two open arms (35cm*5cm*15cm) and two closed arms (35cm*5cm). The middle area of ​​the cross maze is a fully open area (5cm*5cm). The entire cross maze is 50cm above the ground. At the beginning of the experiment, the mice were placed in the middle area of ​​the maze, facing the open arms. Then, the number of times the mice entered the open arms and closed arms within 7 minutes, the time they stayed in the open arms and closed arms, and the time they were still were automatically monitored. The time the mice stayed in the open arms was used as an anxiety indicator. The longer the mice stayed in the open arms, the lower their anxiety level.

[0069] 3) Light and dark box

[0070] The size of the light-dark box device is 50cm*25cm*25cm. It contains two spaces, a light box and a dark box. The partition wall between the two boxes has a 7.5cm*7.5cm door hole for mice to shuttle through. The test time for each mouse is 5 minutes. At the beginning of the test, the mouse is placed in the light box and allowed to explore freely in the device. Monitor the time the mouse stays in the light box, the number of times the light and dark boxes shuttle, and the time of the first entry into the dark room. The time spent in the light box is used as an anxiety indicator. The longer the mouse stays in the light box, the lower the anxiety level.

[0071] 2. Depression-like behavior test (tail suspension test)

[0072] The tail suspension test is widely used to assess despair behavior in rodents. Briefly, mice are suspended by tape about 1 cm from the tip of the tail 30 cm above the ground. The duration of the experiment is 6 min, and the immobility time (no struggling, little body movement) during the suspension process is automatically monitored during the last 5 min. The duration of immobility of mice will be used as an indicator of depression, and the longer the immobility time, the higher the degree of depression of the mice.

[0073] 3. Statistical analysis

[0074] Prism software was used for statistical analysis. In the behavioral experimental results, each group was first checked for outliers, and then a significance analysis was performed after elimination. The blank control group and the model group used an unpaired t-test, while the model group and the three intervention groups used a one-way anova. In order to more accurately compare the significance between different experimental groups, the Z-score method was used to normalize the behavioral results and then compare them, and finally the efficacy of each intervention group was ranked. Taking the open field experiment as an example, the Z-score calculation formula is as follows:

[0075]

[0076] in,

[0077] X: observed values ​​of behavioral indices of mice in the intervention group;

[0078] μ: mean values ​​of behavioral indicators of mice in the model group;

[0079] σ: standard deviation of behavioral indicators of mice in the model group;

[0080] TC: time mice stayed in the open area in the open field test;

[0081] DR: the ratio of the exploration distance of mice in the middle area to the total exploration distance in the open field test;

[0082] Then the elevated maze behavior Z EPM Scoring, light-dark box behavior Z LDB Scoring and tail suspension test Z TST Score, because the Z score of anxiety-like behavior (such as Z OF , Z EPM , Z LDB ) indicates that the individual has a lower risk of anxiety; in addition, a higher Z score for depression-like behavior indicates that the individual has a higher risk of depression. A The score is the weighted average of the Z scores of each behavior, that is, Z A =(Z OF +Z EPM +Z LDB ) / 3. The overall anxiety and depression behavior is Z T The score is the mean of the sum of the anxiety behavior Z score minus the depression behavior Z score, that is, Z T =(Z OF +Z EPM +Z LDB --Z TST ) / 4.

[0083] 5. Results and analysis

[0084] 5.1 Effects of different nutritional components on anxiety-like behaviors in stressed mice

[0085] 5.1.1 Open field experiment

[0086] like Figure 1 As shown in the open field test, the time that mice spent in the middle area of ​​the open field after stress induction was significantly reduced compared with the blank group ( Figure 1 ); After intervention with intervention substance 2 (LF), the time mice stayed in the middle area of ​​the open field was significantly higher than that of the model group. In addition, the number of times mice entered the middle area of ​​the open field increased significantly in the intervention substance 1 and intervention substance 3 groups. The above results indicate that lactoferrin LF and its combination with 2'-FL can significantly improve the anxiety-like behavior of mice in the open field, and 2'-FL also exhibits potential antianxiety effects ( Figure 1).

[0087] 5.1.2 Elevated maze test

[0088] like Figure 4 As shown, the results of the elevated maze experiment showed that compared with the blank control group, the time mice stayed in the open arm after stress induction was significantly reduced, indicating that mice showed anxiety-like behavior in the elevated maze after stress induction; compared with the model group, the time mice stayed in the open arm in the intervention 1 (2'-FL), intervention 2 (LF) and intervention 3 (2'-FL combined with LF) groups was significantly increased, and was comparable to the blank control group; the above results indicate that intervention 1, intervention 2 and intervention 3 can significantly alleviate the anxiety-like behavior of mice in the elevated maze.

[0089] 5.1.3 Light and dark box experiment

[0090] like Figure 7 As shown, in the light-dark box experiment, compared with the blank group, the time that mice stayed in the light box after stress induction was significantly reduced, indicating that mice showed anxiety-like behavior in the light-dark box after stress induction; compared with the model group, the time that mice stayed in the light box in the intervention 1 (2'-FL), intervention 2 (LF) and intervention 3 (2'-FL combined with LF) groups was significantly increased, and was comparable to that of the blank control group; the above results indicate that intervention 1, intervention 2 and intervention 3 significantly alleviated the anxiety-like behavior of mice in the light-dark box.

[0091] 5.2 Effects of different nutritional components on depressive-like behavior in stressed mice (tail suspension test)

[0092] like Fig.10 As shown, the results of the mouse tail suspension experiment showed that compared with the blank control group, the immobility time of mice in the stress-induced model group was significantly increased, indicating that the mice showed depressive-like behavior after stress induction; compared with the model group, intervention 1 (2'-FL), intervention 2 (LF) and intervention 3 (2'-FL combined with LF) could significantly reduce the immobility time of mice, and were close to the blank control group; the above results indicate that intervention 1, intervention 2 and intervention 3 can significantly improve the depressive-like behavior of mice during tail suspension.

[0093] 5.3 Comparison of behavioral Z scores

[0094] As shown in Table 1, based on Z A The percentage of individuals with scores above the mean of this experiment was counted. The results showed that 40% (4 / 10) of the intervention group were in the intervention 1 group, 60% (6 / 10) were in the intervention 2 group, and 44.4% (4 / 9) were in the intervention 3 group. This indicates that intervention 2 performed best in the anxiety-like behavior Z score, followed by intervention 3, and finally intervention 1. TThe scores were the mean of this experiment, and the percentage of individuals with scores above the mean was statistically analyzed. The results showed that intervention 1 had 60% (6 / 10), intervention 2 had 50% (5 / 10), and intervention 3 had 44.4% (4 / 9). This shows that intervention 1 performed best in the depressive-like behavior Z score, followed by intervention 2, and finally intervention 3.

[0095] Table 1. Behavioral Z score table of each intervention group

[0096]

[0097] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.

Claims

1. A nutritional composition for regulating mood, characterized in that: The invention comprises lactoferrin and 2'-fucosyllactose, and the weight ratio of lactoferrin to 2'-fucosyllactose is 1:2-9.

2. The nutritional composition according to claim 1, characterized in that The weight ratio of lactoferrin to 2'-fucosyllactose is 1:2-6.

3. The nutritional composition according to claim 2, characterized in that The weight ratio of lactoferrin to 2'-fucosyllactose is 1:

6.

4. A product, characterized in that The nutritional composition comprising any one of claims 1 to 3 is at least one of a food, a medicine and a nutritional product.

5. The product according to claim 4, characterized in that The dosage forms of the medicine include pills, capsules, granules, oral liquids, powders, tablets, lozenges, and sugar lozenges.

6. The product according to claim 5, characterized in that The dosage form is selected from capsules, tablets or pills.

7. The product according to claim 5, characterized in that The medicine also includes auxiliary materials.

8. The product according to claim 7, characterized in that The auxiliary materials include at least one of a disintegrant, a binder, a flavoring agent, a suspending agent, a foaming agent, a pH adjuster, a lubricant, a glidant, an antioxidant, and a corrosion inhibitor.

9. The method for preparing the nutritional composition according to any one of claims 1 to 3, characterized in that: The method comprises the following steps: mixing lactoferrin and 2'-fucosyllactose according to a certain proportion, and sieving the mixture.

10. Use of the nutritional composition according to any one of claims 1 to 3 or the product according to any one of claims 4 to 8 in the preparation of a medicament for preventing or treating anxiety or depression.

11. The use according to claim 10, characterized in that: The depression is selected from psychogenic depression, endogenous depression, hypochondriacal depression, anxious depression, pseudodementia-type depression, and chronic depression.

12. The use according to claim 10, characterized in that: The depression symptoms include: 1) Psychological changes: mood changes, intense sadness, hopelessness, mental dullness, difficulty concentrating, pessimism, agitation, anxiety, irritability, guilt, feelings of worthlessness, suicidal thoughts or attempts; 2) Physical symptoms: insomnia, anorexia, decreased appetite, weight loss, weight gain, decreased energy and libido, fatigue, irritability, aches, pains, cramps.

Images